Contact CGI:Contact Us | Email


Stock Information

Symbol Market Last Change Volume
CGIX Nasdaq

View Stock Information

Latest Webcast

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see

Latest Press Releases

  • Nov20

    Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update Read More

  • Oct24

    Cancer Genetics, Inc. Announces Strategic Transactions Read More

  • Oct24

    Cancer Genetics Announces 1-for-30 Reverse Stock Split Read More

Latest Events

  • Aug14

    2nd Quarter 2018 Conference Call
    Date: August 14, 2018

  • May15

    1st Quarter 2018 Conference Call
    Date: May 15, 2018

  • Apr02

    4th Quarter and Fiscal Year 2017 Conference Call
    Date: April 2, 2018


Cancer Genetics, Inc.
201 Route 17 North
2nd Floor
Rutherford, NJ 07070

Investor Relations

Discover Cancer Genetics Incorporated »

Our Research
With unparalleled excellence in oncology, our team is dedicated to empowering personalized cancer treatment.
Our Media
Stay current with the latest company news, articles, videos, and webinars.
Our Partners
CGI has established strong research collaborations with key thought leaders in oncology and major cancer centers in the U.S. and abroad.
Click here to login and view your reports.